Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | GPR39 | O43194 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | KDM4B | O94953 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038015 | 0.91 | EGLN1 (0.49) | EGLN1ROCK2MGLLACVR1KDM4A | |
| SCHEMBL3037229 | 0.91 | EGLN1 (0.46) | EGLN1MGLLMAPTMAPK1HTT | |
| SCHEMBL3036599 | 0.89 | EGLN1 (0.48) | EGLN1MAPTACVR1ERCC1ERCC4 | |
| SCHEMBL3033554 | 0.86 | EGLN1 (0.68) | EGLN1MGLLMAPK1ACVR1 | |
| SCHEMBL3030437 | 0.84 | HTR3A (0.52) | EGLN1MGLLMAPTMAPK1HTT | |
| SCHEMBL3036662 | 0.83 | TUBB4A (0.48) | EGLN1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL3026678 | 0.83 | TUBB4A (0.48) | EGLN1MAPT | |
| SCHEMBL3027794 | 0.83 | TUBB4A (0.48) | EGLN1MAPTNPSR1KDM4AKDM4B | |
| SCHEMBL3033389 | 0.83 | PARP1 (0.41) | EGLN1KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL3036658 | 0.83 | HTR3A (0.55) | EGLN1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 7/4885ROCK2 1458/4885MGLL 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.